Dr. Mariano Barbacid's team at the Spanish National Cancer Research Centre (CNIO) found a triple-drug combination that completely and durably eliminated pancreatic ductal adenocarcinoma (PDAC) tumors in preclinical mouse models.
The three-drug combination consists of:
- Daraxonrasib (RMC-6236): A targeted inhibitor for mutant KRAS (the oncogene driving over 90% of pancreatic cancers).
- Afatinib: An approved lung cancer drug that blocks upstream EGFR signaling (which tumors often use as an escape route).
- SD36: An experimental protein degrader targeting the STAT3 survival pathway.
No comments:
Post a Comment